COMP <GO>
ARQT vs INDV // RSI-14 & 200D SMA MOMENTUM
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Indivior Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ARQT 6
— INDV 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ARQT
LAST: $32.07 (+0.31%) • MKT CAP: $4.03B
rsi-technicals
66.0
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
rsi-technicals
52.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. INDV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | INDV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 80.20% | +10.00 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | 62.20% | -65.20 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | -2.24% | +2.08 | ARQT | /fcf-yield <GO> |
| Operating Margin | -3.30% | 21.10% | -24.40 | INDV | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 16.90% | -21.20 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 4.30% | +87.00 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 3.13 | +4.65 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 66.0 | 52.3 | +13.70 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 18.4x | +5.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $4.17B | -$144.0M | INDV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | INDV REV | ARQT GROSS % | INDV GROSS % | ARQT FCF | INDV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $1.24B | 90.2% | 80.2% | -$6.3M | -$93.0M |
| FY 2024 | $196.5M | $1.19B | 90.3% | 80.6% | -$112.3M | $7.0M |
| FY 2023 | $59.6M | $1.09B | — | — | -$249.7M | -$349.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
INDV // BETA 1.15